Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Samples Reveal Gene Expression Pattern Diagnostic for Lung Cancer

By LabMedica International staff writers
Posted on 08 Mar 2017
Differences in gene expression that can be detected in nasal tissue from smokers or nonsmokers suggest that it may be possible to diagnose lung cancer from samples collected on nasal swabs.

Investigators at Boston University Medical Center had previously derived and validated a bronchial epithelial gene expression biomarker to detect lung cancer in current and former smokers. More...
Given that gene expression in bronchial and nasal epithelial is similarly altered by cigarette smoke exposure, they sought to determine if cancer-associated gene expression might also be detectable in the more readily accessible nasal epithelium.

Towards this end, the investigators collected nasal epithelial brushings from current and former smokers undergoing diagnostic evaluation for pulmonary lesions suspicious for lung cancer in the Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer (AEGIS) clinical trials. Gene expression was profiled using microarrays.

Results revealed that 535 genes were differentially expressed in the nasal epithelium of AEGIS patients diagnosed with lung cancer versus those with benign disease after one year of follow-up. Using bronchial gene expression data from the AEGIS patients, the investigators found statistically significant concordant cancer-associated gene expression alterations between the two airway sites. Differentially expressed genes in the nose were enriched for genes associated with the regulation of apoptosis and immune system signaling.

A nasal lung cancer classifier that combined clinical factors (age, smoking status, time since quitting, mass size) and nasal gene expression (30 genes) was statistically more significant and sensitive than a clinical-factor only model.

"Our findings clearly demonstrate the existence of a cancer-associated airway field of injury that also can be measured in nasal epithelium," said senior author Dr. Marc Lenburg, professor of medicine at Boston University Medical Center. "We find that nasal gene expression contains information about the presence of cancer that is independent of standard clinical risk factors, suggesting that nasal epithelial gene expression might aid in lung cancer detection. Moreover, the nasal samples can be collected non-invasively with little instrumentation or advanced training."

The study was published in the February 27, 2017, online edition of the Journal of the National Cancer Institute.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Hematology Consumables
Bioblood Devices
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.